Traws Pharma director granted 33,435 stock options

Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock.

Accepted by SEC EDGAR 03/10/2026 - 07:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma director John Harold Leaman received a stock option grant for 33,435 shares of common stock. The options have an exercise price of $1.60 per share and were awarded at no upfront cost as compensation. According to the award terms, the options will vest 100% on the first anniversary of the March 8, 2026 grant date, after which they become exercisable. Following this grant, Leaman holds 33,435 stock options directly.

Insights

Equity Compensation Analyst

Routine director option grant with time-based vesting and standard economics.

The filing shows John Harold Leaman, a director of Traws Pharma, Inc., receiving 33,435 stock options as a compensation award under the 2021 Incentive Compensation Plan. The exercise price is set at $1.60 per share, aligning his potential upside with future share performance.

The options vest 100% on the first anniversary of the March 8, 2026 grant date, meaning they are not exercisable until that time. This is typical time-based vesting intended to support ongoing board service and alignment rather than signaling a market view on the stock.

After this transaction, Leaman’s reported derivative holdings consist of these 33,435 options, with an expiration date in 2036. Subsequent company filings may provide additional context on total director compensation and any future option exercises or additional grants.

Insider Trade Summary

Grant/Award: 33,435 shares

Grant/Award 1 txn

Insider Leaman John Harold

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	33,435	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 33,435 contracts (Direct)

Holdings Before and After: Stock Option (right to buy), 0 to 33,435 contracts (Direct)

Footnotes (1)

1. F1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Traws Pharma (TRAW) director John Harold Leaman receive in this Form 4?

John Harold Leaman received a grant of 33,435 stock options for Traws Pharma common stock. The options were awarded as compensation under the 2021 Incentive Compensation Plan, giving him the right to buy shares at a fixed $1.60 exercise price in the future.

What is the exercise price and term of John Harold Leaman’s Traws Pharma options?

The granted stock options have an exercise price of $1.60 per Traws Pharma share. They were granted on March 8, 2026 and are scheduled to expire on March 8, 2036, giving a 10-year window to exercise once vested and otherwise in force.

When do John Harold Leaman’s Traws Pharma (TRAW) stock options vest?

The 33,435 stock options awarded to John Harold Leaman vest 100% on the first anniversary of the March 8, 2026 grant date. This means they become fully exercisable one year after grant, assuming continued service and satisfaction of the plan’s vesting conditions.

How many Traws Pharma derivative securities does John Harold Leaman hold after this Form 4?

Following this transaction, John Harold Leaman holds 33,435 stock options in Traws Pharma directly. These options relate to an equal number of underlying common shares and were granted as a single award under the company’s 2021 Incentive Compensation Plan, as amended or restated.

Is this Traws Pharma (TRAW) Form 4 a market purchase or sale of stock?

This Form 4 does not show a market purchase or sale of Traws Pharma shares. It reports a grant of 33,435 stock options as compensation, with a $1.60 exercise price, rather than an open-market trade, so it reflects equity-based pay rather than trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Leaman John Harold

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC.

12 PENNS TRAIL

(Street)

NEWTOWN PA 18940

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	03/08/2026		A		33,435		03/08/2027(1)	03/08/2036	Common Stock	33,435	$0	33,435	D

Explanation of Responses:

1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

	/s/ John H. Leaman	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.